Population pharmacokinetics of colistin methanesulfonate in rats: Achieving sustained lung concentrations of colistin for targeting respiratory infections

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 5087-5095

  Yapa, Shalini W S ^a   Li, Jian ^a   Porter, Christopher J H ^a   Nation, Roger L ^a   Patel, Kashyap ^a   McIntosh, Michelle P ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; FRACTIONATION; LUNG; LUNG ALVEOLUS EPITHELIUM; LUNG EPITHELIAL LINING FLUID; LUNG LAVAGE; MALE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PLASMA; PRIORITY JOURNAL; RAT; RESPIRATORY TRACT INFECTION; SYSTEMIC CIRCULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; LUNG; MALE; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY TRACT INFECTIONS;

EID: 84884254267     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01127-13     Document Type: Article

References (49)

1. Geller DE. 2009. Aerosol antibiotics in cystic fibrosis. Respir. Care 54: 658-670.
2. Antoniu SA, Cojocaru I. 2012. Inhaled colistin for lower respiratory tract infections. Expert Opin. Drug Deliv. 9:333-342.
3. Labiris N, Dolovich M. 2003. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56:588-599.
4. Palmer LB. 2011. Aerosolized antibiotics in the intensive care unit. Clin. Chest Med. 32:559-574.
5. Hewer SL. 2012. Inhaled antibiotics in cystic fibrosis: what's new? J. R. Soc. Med. 105(Suppl 2):S19 -S24.
6. Li J, Nation R, Milne R, Turnidge J, Coulthard K. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25.
7. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341.
8. Landman D, Georgescu C, Martin DA, Quale J. 2008. Polymyxins revisited. Clin. Microbiol. Rev. 21:449-465.
9. Nation RL, Li J. 2009. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22:535-543.
10. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1953-1958.
11. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589- 601.
12. Hansen CR, Pressler T, Hoiby N. 2008. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J. Cyst. Fibros. 7:523-530.
13. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. 2000. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16:749-767.
14. Doring G, Hoiby N. 2004. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cyst. Fibros. 3:67-91.
15. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME. 2008. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir. Med. 102:407-412.
16. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. 2010. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilatorassociated pneumonia: a comparative cohort study. Clin. Microbiol. Infect. 16:1230-1236.
17. Marchand S, Gobin P, Brillault J, Baptista S, Adier C, Olivier JC, Mimoz O, Couet W. 2010. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob. Agents Chemother. 54:3702-3707.
18. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H. 2006. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 57:306- 311.
19. Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ. 2012. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 38:1779-1786.
20. Brain JD, Knudson DE, Sorokin SP, Davis MA. 1976. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ. Res. 11:13-33.
21. Dudhani RV, Nation RL, Li J. 2010. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J. Antimicrob. Chemother. 65:1412-1415.
22. Wallace SJ, Li J, Nation RL, Rayner CR, Taylor D, Middleton D, Milne RW, Coulthard K, Turnidge JD. 2008. Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob. Agents Chemother. 52:1159-1161.
23. Li J, Milne R, Nation R, Turnidge J, Coulthard K, Johnson D. 2001. A simple method for the assay of colistin in human plasma, using precolumn derivatization with 9-fluorenylmethyl chloroformate in solidphase extraction cartridges and reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 761:167-175.
24. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. 2002. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob. Agents Chemother. 46:3304-3307.
25. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as a marker of dilution. J. Appl. Physiol. 60:532-538.
26. Bauer R. 2008. S-ADAPT/MCPEM user's guide (version 1.57). Software for pharmacokinetic, pharmacodynamic and population data analysis. Biomedical Simulations Resource, Berkeley, CA.
27. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504.
28. Marchand S, Lamarche I, Gobin P, Couet W. 2010. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J. Antimicrob. Chemother. 65:1753-1758.
29. Li J, Milne R, Nation R, Turnidge J, Smeaton T, Coulthard K. 2004. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J. Antimicrob. Chemother. 53:837-840.
30. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob. Agents Chemother. 47:1766-1770.
31. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. 2008. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob. Agents Chemother. 52:3047- 3051.
32. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. 2003. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob. Agents Chemother. 47:1364-1370.
33. He H, Li J, Nation R, Jacob J, Chen G, Lee H, Tsuji B, Thompson P, Roberts K, Velkov T, Li J. 7 June 2013. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J. Antimicrob. Chemother. [Epub ahead of print.] doi:10.1093/jac/dkt207.
34. Gales AC, Jones RN, Sader HS. 2011. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J. Antimicrob. Chemother. 66:2070-2074.
35. Ziv G, Nouws JF, van Ginneken CA. 1982. The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves. J. Vet. Pharmacol. Therapeut. 5:45-58.
36. Kunin CM, Bugg A. 1971. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J. Infect. Dis. 124:394-400.
37. Craig WA, Kunin CM. 1973. Dynamics of binding and release of the polymyxin antibiotics by tissues. J. Pharmacol. Exp. Ther. 184:757-765.
38. Anderson MW, Orton TC, Pickett RD, Eling TE. 1974. Accumulation of amines in the isolated perfused rabbit lung. J. Pharmacol. Exp. Ther. 189: 456-466.
39. Vestal RE, Kornhauser DM, Shand DG. 1980. Active uptake of propranolol by isolated rabbit alveolar macrophages and its inhibition by other basic amines. J. Pharmacol. Exp. Ther. 214:106-111.
40. Wilson AG, Sar M, Stumpf WE. 1982. Autoradiographic study of imipramine localization in the isolated perfused rabbit long. Drug Metab. Dispos. 10:281-283.
41. Yoshida H, Okumura K, Kamiya A, Hori R. 1989. Accumulation mechanism of basic drugs in the isolated perfused rat lung. Chem. Pharm. Bull. 37:450-453.
42. Schanker LS. 1978. Drug absorption from the lung. Biochem. Pharmacol. 27:381-385.
43. Enna SJ, Schanker LS. 1972. Absorption of drugs from the rat lung. Am. J. Physiol. 223:1227-1231.
44. Burton JA, Schanker LS. 1974. Absorption of antibiotics from the rat lung. Proc. Soc. Exp. Biol. Med. 145:752-756.
45. Tronde A, Norden B, Marchner H, Wendel AK, Lennernas H, Bengtsson UH. 2003. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J. Pharm. Sci. 92:1216-1233.
46. Tronde A, Norden B, Jeppsson AB, Brunmark P, Nilsson E, Lennernas H, Bengtsson UH. 2003. Drug absorption from the isolated perfused rat lung-correlations with drug physicochemical properties and epithelial permeability. J. Drug Target. 11:61-74.
47. Crandon JL, Kim A, Nicolau DP. 2009. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J. Antimicrob. Chemother. 64:837-839.
48. Keel RA, Crandon JL, Nicolau DP. 2012. Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob. Agents Chemother. 56:3420- 3422.
49. Valcke Y, Pauwels R, Van der Straeten M. 1990. The penetration of aminoglycosides into the alveolar lining fluid of rats. The effect of airway inflammation. Am. Rev. Respir. Dis. 142:1099-1103.